Dipeptidyl Peptidase Inhibitors

Dipeptidyl peptidase inhibitors are a class of pharmaceutical compounds that have been developed to treat type 2 diabetes mellitus These inhibitors work by blocking the activity of the enzyme dipeptidyl peptidase-4 (DPP-4) which is responsible for breaking down incretin hormones By inhibiting DPP-4 these medications increase the levels of active incretin hormones such as glucagon-like peptide-1 (GLP-1) which in turn stimulate insulin secretion and reduce blood glucose levels In addition to their glucose-lowering effects dipeptidyl peptidase inhibitors have also been shown to promote weight loss and exhibit a low risk of hypoglycemia With their unique mechanism of action and proven efficacy dipeptidyl peptidase inhibitors have become an essential component of the treatment regimens for patients with type 2 diabetes

Get A Quote

Products Application Supporting Data Resources Related Products

Products

Catalog Number	Chemical Name	CAS #	Price
EI-0154	Alogliptin benzoate	850649-62-6	Online Inquiry
EI-0739	Diprotin A	90614-48-5	Online Inquiry
EI-0740	Diprotin B	90614-49-6	Online Inquiry
EI-0762	DPP IV Inhibitor, K 579	440100-64-1	Online Inquiry
EI-0763	DPP IV Inhibitor, NVP DPP 728	247016-69-9	Online Inquiry
EI-0764	DPPIV Inhibitor, P32/98	136259-20-6	Online Inquiry
EI-1347	Linagliptin	668270-12-0	Online Inquiry
EI-1469	MK-3102	1226781-44-7	Online Inquiry
EI-1956	Saxagliptin	361442-04-8	Online Inquiry
EI-2016	Sitagliptin Phosphate Monohydrate	654671-77-9	Online Inquiry
EI-2109	Talabostat mesylate	150080-09-4	Online Inquiry
EI-2143	Teneligliptin	760937-92-6	Online Inquiry
EI-2204	Trelagliptin succinate	1029877-94-8	Online Inquiry
EI-2278	Vildagliptin	274901-16-5	Online Inquiry

Application

Dipeptidyl peptidase inhibitors or DPP-4 inhibitors have a wide range of applications in the field of medicine One key application is in the management of type 2 diabetes By inhibiting the activity of DPP-4 enzymes these inhibitors help regulate blood sugar levels by increasing the concentration of incretin hormones which stimulate insulin release and decrease the production of glucagon

Additionally DPP-4 inhibitors have shown promise in the treatment of other metabolic disorders such as obesity and non-alcoholic fatty liver disease These inhibitors have been found to improve insulin sensitivity reduce inflammation and prevent the accumulation of fat in the liver

Furthermore DPP-4 inhibitors have potential applications in the field of cancer research Studies have suggested that these inhibitors may inhibit tumor growth and metastasis by targeting the signaling pathways involved in cancer cell proliferation and migration

Overall the versatile applications of DPP-4 inhibitors make them a valuable tool in the management of diabetes and other metabolic disorders as well as a potential therapeutic option for cancer treatment

Supporting Data

Resources

Please note that all services are for research use only. Not intended for any clinical use.

Get a free quote

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.